| Name | Title | Contact Details |
|---|
EHP Inc is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 1996, Principals of Clearwater Living have been actively engaged in the ownership, operation, and development of high-quality senior living communities nationwide. More specifically, the Principals of Clearwater have been an integral part of creating various senior living platforms for operators as part of senior management. In 2011, Clearwater Living was formed for the sole purpose of providing entitled land and developing senior living communities for operators and their financial stakeholders. By combining best practices learned and aligning with top-of-class industry professionals, Clearwater Living`s primary objective is to expedite the process of supplying innovative projects to meet the growing demand of active adult and senior living communities. To further that goal, Clearwater Living and Berkshire Group entered into a joint venture in 2016. Through the joint venture, Clearwater Living will strategically acquire, develop and operate a full range of senior housing communities (including a mix of active adult, independent living, assisted living and memory care) throughout the Western United States. CWL is comprised of a high-performance real estate team utilizing our collective imagination, ingenuity and inventiveness in everything we do. Our passion is to create and manage high-quality senior living communities uniquely positioned and designed to complement their community and neighborhood culture.
Great Lakes Health Plan (GLHP) has been offering health care services to members eligible for Medicaid in the State of Michigan since March 1996. Our service area covers members living in 23 counties, including: Allegan, Berrien, Branch, Cass, Calhoun,
plaza dental is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.